[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@DaiichiSankyoUS](/creator/twitter/DaiichiSankyoUS)
"#BREAKINGNEWS: The FDA accepted the sBLA for our HER2 directed DXd #ADC followed by a combination regimen for the treatment of adult patients w/ high-risk #HER2 positive early-stage breast cancer prior to surgery in collaboration w/ @AstraZenecaUS. Click to learn more"  
[X Link](https://x.com/DaiichiSankyoUS/status/1973346517252767839) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-01T11:17Z 4424 followers, XXX engagements


"#BREAKINGNEWS: Today we announced the establishment of the Daiichi Sankyo Research Institute in San Diego marking our third research institute outside of our flagship research center in Japan. Click the image to learn more. #ResearchInstitute #PharmaResearch"  
[X Link](https://x.com/DaiichiSankyoUS/status/1973737189914866085) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-02T13:09Z 4426 followers, XXX engagements


"#BREAKINGNEWS: Today we announced positive topline results from the TROPION-Breast02 phase X trial for patients with locally recurrent inoperable or metastatic triple negative breast cancer (#TNBC) in collaboration with @AstraZenecaUS. Click the image to learn more. #TNBC"  
[X Link](https://x.com/DaiichiSankyoUS/status/1975158662407840209) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-06T11:18Z 4427 followers, XXX engagements


"#BREAKINGNEWS: Daiichi Sankyo joins @BioLabs the leading international innovation platform and network of premier shared laboratory spaces as Platinum Sponsor; providing BioLabs with direct access to Daiichi Sankyo scientific leaders and expertise. Click the image for more"  
[X Link](https://x.com/DaiichiSankyoUS/status/1975520302286450785) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-07T11:15Z 4426 followers, XXX engagements


"#NEWS: Throughout @MyESMO we will present more than XX abstracts including two back-to-back presentations during Presidential Symposium I featuring data from the DESTINY-Breast11 & DESTINY-Breast05 phase X trials & late-breaking data from the TROPION-Breast02 phase X trial"  
[X Link](https://x.com/DaiichiSankyoUS/status/1977697830606361036) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-13T11:28Z 4426 followers, XXX engagements


"#BREAKINGNEWS: Today during a mini oral session at @MyESMO Daiichi Sankyo announced initial results from one substudy of the TROPION-PanTumor03 phase X trial in patients with locally advanced or metastatic urothelial cancer. Click to learn more. #BladderCancer #ESMO25"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979189488745419041) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-17T14:15Z 4426 followers, XXX engagements


"#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced the first neoadjuvant data from the DESTINY-Breast11 phase X trial for patients with high-risk HER2 positive early-stage breast cancer. Click to learn more. #HER2"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979558640379105786) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-18T14:42Z 4426 followers, XXX engagements


"#BREAKINGNEWS: Today during Presidential Symposium I at @MyESMO Daiichi Sankyo announced new post-neoadjuvant data from the DESTINY-Breast05 phase X trial in patients with HER2 positive high-risk early breast cancer. Click the image to learn more. #CancerResearch #HER2"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979561741869863357) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-18T14:54Z 4426 followers, XXX engagements


"#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced late-breaking data from the TROPION-Breast02 phase X trial in patients w/ metastatic triple negative breast cancer (#TNBC) in the first-line treatment setting. Click to learn more. #ESMO25"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979867443532288510) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-19T11:09Z 4426 followers, XXX engagements


"#BREAKINGNEWS: Today at @MyESMO Daiichi Sankyo announced results from the phase X part of the REJOICE-Ovarian01 phase 2/3 trial in certain patients with platinum-resistant ovarian cancer. Click the image to learn more. #OvarianCancer #CancerResearch #ESMO25"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979897206326059271) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-19T13:07Z 4426 followers, XXX engagements


"#BREAKINGNEWS: During @MyESMO Daiichi Sankyo announced data from our TA-MUC1 directed DXd ADC first-in-human phase 1/2 trial. This is the sixth DXd ADC from our oncology pipeline. Click to learn more & follow us during #ESMO25 for the latest data updates from Daiichi Sankyo"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979901319180902826) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-19T13:23Z 4426 followers, XXX engagements